Treatment advances of sepsis‑induced myopathy (Review)
- This article is part of the special Issue: FUNDAMENTAL AND MODERN RESEARCHES IN SEPSIS BASED ON INTERDISCIPLINARY APPROACHES
- Authors:
- Published online on: November 25, 2024 https://doi.org/10.3892/br.2024.1897
- Article Number: 19
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Sepsis‑induced myopathy (SIM) is a muscle disease caused by multiple pathological and physiological mechanisms associated with sepsis. The pathogenesis of SIM is extremely complex and still unclear, making treatment challenging. At present, clinical treatment includes early functional exercise, respiratory muscle strength training, regulation of nutritional structure and functional electrical stimulation. Drugs targeting the regulation of the ubiquitin‑proteasome system, autophagy‑lysosome system, calpain and caspase activation pathways, have provided potential therapeutic targets for the treatment of muscle atrophy. Stem cell transplantation therapy brings new hope for the treatment of SIM.
